Mycobacterium vaccae Reduces Scratching Behavior but not the Rash in NC Mice with Eczema: A Randomized, Blinded, Placebo-Controlled Trial  Peter D. Arkwright, Chie Fujisawa, Akane Tanaka, Hiroshi Matsuda  Journal of Investigative Dermatology  Volume 124, Issue 1, Pages 140-143 (January 2005) DOI: 10.1111/j.0022-202X.2004.23561.x Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Scatterplot showing the correlation between clinical eczema score and scratch frequency during an 18-min observation period in NC/Nga mice. Simultaneous measurements of the two scores were made on individual mice between 8 and 26 wk of age. N=120 measurements. Calculated linear regression line is shown. Journal of Investigative Dermatology 2005 124, 140-143DOI: (10.1111/j.0022-202X.2004.23561.x) Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Comparative effects of placebo, SRP299 (0.01 mg dose), and SRP299 (0.1 mg dose) on the age of onset (weeks) of eczema (clinical eczema scores >2) in NC/Nga mice. Bars represent median value. Journal of Investigative Dermatology 2005 124, 140-143DOI: (10.1111/j.0022-202X.2004.23561.x) Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 3 Comparative effects of placebo, SRP299 (0.01 mg dose), and SRP299 (0.1 mg dose) on the peak severity of eczema in NC/Nga mice. (A) Peak clinical eczema score, (B) peak scratch frequency. Bars represent median value. *p<0.05 (Kruskal–Wallis H test). Journal of Investigative Dermatology 2005 124, 140-143DOI: (10.1111/j.0022-202X.2004.23561.x) Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions